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Abstract During embryogenesis, the maturation of neuroblasts
into neurones is accompanied by the down-regulation of vimentin
and by the expression of neuronal microtubular proteins. Here,
we show that human adrenal cortex SW13 cells express LIII-
tubulin, MAP2b and tau. Analysis of vimentin-positive and
-negative subclones of SW13 cells revealed that, under defined
cultured conditions, LIII-tubulin and MAP2b were present only in
vimentin-deficient cells and that LIII-tubulin repression occurred
at the transcriptional level in vimentin-positive cells. These
results suggest that vimentin repression and LIII-tubulin expres-
sion are co-ordinated by an upstream mechanism relevant to the
control of cytoskeletal protein expression during neuronal
development.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
During embryogenesis, di¡erentiation of neuroblasts into
neurones is accompanied by the sequential expression of cy-
toskeletal proteins that are required for morphological trans-
formation, in particular, for the extension of axons and den-
drites. Developmental regulation of cytoskeletal proteins is
especially clear for intermediate ¢lament proteins. Nestin is
the ¢rst intermediate ¢lament protein to be expressed in neu-
roblasts [1] and is gradually replaced by vimentin (for a re-
view, see [2]). Neuronal intermediate ¢lament proteins are
then progressively expressed in post-mitotic neurones, ¢rst
K-internexin, followed by neuro¢lament subunits. Initially,
NF-L and NF-M are co-expressed, the third subunit, NF-H
appears shortly before axons reach their targets.
Like intermediate ¢lament proteins, individual tubulin iso-
forms have a regulated pattern of expression during matura-
tion of neuronal progenitor cells into neurones and this is best
illustrated for LIII-tubulin. Like other tubulin isoforms, LIII-
tubulin is coded by its own gene and di¡ers from other L-
tubulin isoforms by a speci¢c 15 amino acid C-terminal se-
quence [3]. LIII-Tubulin expression starts at the late stages of
neuronal di¡erentiation and is sustained in mature neurones;
in addition, LIII-tubulin expression begins earlier in peripheral
neurones than in central neurones [4,5]. The role of LIII-tubu-
lin in the properties and functions of microtubules is still
unclear, but it may modulate their dynamic properties. In
vitro studies have shown that microtubules assembled from
KLIII-tubulin are considerably more dynamic than microtu-
bules made of K-tubulin combined with other L-tubulin iso-
forms [6]. Therefore, LIII-tubulin may be implicated in the
regional variations in dynamic properties of microtubules
that exist along growing axons [7].
Expression of LIII-tubulin during neurogenesis is controlled
by a negative regulatory element, the neurone-restrictive si-
lencer element (NRSE), a cis-acting silencer thought to medi-
ate the transcriptional repression of multiple neuronal-speci¢c
genes [8^10]. On the other hand, expression of the vimentin
gene exhibits a complex regulation, involving the combination
of both positive and negative elements [11^15]. Here, we show
that LIII-tubulin is expressed in a cell line originating from an
adenocarcinoma of the human adrenal cortex and that tran-
scriptional activation of LIII-tubulin is conditional to tran-
scriptional repression of vimentin. These results suggest that
vimentin repression and LIII-tubulin expression are tightly
linked at the transcriptional level. Such a co-ordinated up-
stream mechanism would be highly signi¢cant for the control
of sequential cytoskeletal protein expression during neuronal
development.
2. Materials and methods
2.1. Cell culture
The human adrenal adenocarcinoma cell line, SW13, was obtained
from the European Animal Cell Culture Collection (Porton Down,
UK). SW13 cells express vimentin in a mosaic pattern and the original
population comprises vimentin-positive and vimentin-negative cells
[16]. A vimentin-negative subclone of SW13 cells, SW13vim3, was
selected after limiting dilution cloning [17] and a vimentin-positive
clone (SW13vim, cl.1 [18]) was kindly provided by Dr Robert Evans
(University of Colorado, Boulder, CO, USA). Cells were grown in
DMEM supplemented with 10% heat-inactivated foetal bovine serum
(Gibco BRL/Life Technologies) in a humidi¢ed atmosphere of 5%
CO2/95% air. In some experiments, cells were cultured in phenol
red-free DMEM supplemented with dextran-coated charcoal (DCC)-
treated serum.
2.2. RNA isolation and Northern blotting
Total RNA was extracted from cultured cells using the phenol/
chloroform/isoamyl alcohol method [19]. For Northern blotting anal-
ysis, 15 Wg of total RNA from each sample was separated on 1%
agarose/formaldehyde gels and vacuum-blotted onto GeneScreen-
Plus Nylon membranes (DuPont NEN). Membranes were then hybri-
dised with a 32P-labeled vimentin probe. The vimentin probe used was
a 1.8 kb human vimentin cDNA fragment corresponding to the entire
coding region and was excised by EcoRI restriction digestion from the
pFB4.2 plasmid [20] (obtained from Dr Robert Evans). Labeling of
the probe was carried out using the Prime-It1 II Random Primer
Labeling kit (Stratagene) according to the manufacturer’s instructions.
After hybridisation, membranes were washed to a ¢nal stringency of
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0.2USSC. For autoradiography, membranes were exposed for 1 day
on Kodak X-Omat ¢lm with an intensifying screen at 370‡C.
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis of tubulin transcripts
For RT-PCR, total RNA was treated with DNase I (ampli¢cation
grade, Gibco BRL) and reverse-transcribed with 15 U of AMV re-
verse transcriptase (Promega) for 45 min at 42‡C in 10 mM Tris^HCl,
pH 8.8, 50 mM KCl, 0.1% Triton X-100, 5 mM MgCl2, 1 mM of all
four dNTPs containing 25 U of rRNasin. PCR was carried out using
3 Wl of the reverse transcription reaction mixture in a ¢nal volume of
50 Wl using 2.5 U of cloned Pyrococcus furiosus (Pfu) DNA polymer-
ase (Stratagene). PCR ampli¢cation mixture contained 20 pmol of
each primer (see below), 200 nM of each dNTP, 20 mM Tris^HCl,
pH 8.8, 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Triton
X-100 and 0.1 mg/ml BSA. Double-stranded DNA was denatured at
95‡C for 5 min and 30 PCR cycles were performed with the following
program: 94‡C for 30 s, 65‡C for 30 s and 72‡C for 2 min. Finally,
reaction mixtures were incubated at 72‡C for 3 min. PCR products
were analysed by electrophoresis in 2.5% low melting point NuSieve
agarose gels (FMC BioProducts, Rockland, ME, USA). PX174 RF
DNA/HaeIII fragments ranging from 72 to 1353 bp were used as
DNA size markers.
LIII-Tubulin cDNA was ampli¢ed with the primers 5P-GCCA-
TCTTCCCGCGCAACCG-3P (forward) and 5P-CTTGGGGCCCT-
GGGACTCCG-3P (reverse). The latter corresponds to the region en-
coding the isoform-determining 15 C-terminal amino acids of L-
tubulin [3] and was derived from the nucleotide sequence of human
LIII-tubulin (D.W. Cleveland, personal communication). As a control,
K-tubulin was also ampli¢ed, the primers used were -5P-GCG-
TGAGTGCATCTCATCCT-3P (forward) and -5P-GCTGGCGGTA-
GGTGCCAGTG-3P (reverse). The K-tubulin primers correspond to
a conserved region of human K-tubulin [21] with no homology with
L-tubulin. The expected sizes of the resulting ampli¢cation products
are 195 bp and 253 bp, for LIII- and K-tubulin, respectively.
2.4. Western blotting
Total cell extracts were prepared by homogenising the cells in elec-
trophoresis sample bu¡er (62.5 mM Tris^HCl, 2% sodium dodecyl
sulfate (SDS), 5% L-mercaptoethanol) at 100‡C. For preparation
of heat-stable fractions for tau analysis, cells were resuspended in
Mes/NaCl bu¡er (100 mM 2-(N-morpholino) propanesulfonic acid,
0.5 mM MgCl2, 1 mM EGTA, 1 M NaCl, 2 mM DTT, 0.1 mM
NaVO4, 1 mM PMSF, pH 6.5) and heated at 100‡C for 5 min. After
centrifugation at 16 000Ugav for 25 min, the pellet was discarded and
the supernatant was diluted in electrophoresis sample bu¡er. Proteins
were separated in 10% SDS^polyacrylamide gels and transferred to
nitrocellulose membranes. Membranes were incubated in 10%
skimmed milk in phosphate-bu¡ered saline (PBS) for 1 h at 37‡C.
Subsequent antibody incubations were carried out in PBS containing
5% skimmed milk and 0.5% Tween-20. Membranes were routinely
incubated with primary antibodies overnight at 4‡C, followed by in-
cubation with the appropriate species-speci¢c secondary antibody
conjugated to horseradish peroxidase (Amersham, 1:2000 dilution)
for 1 h at room temperature. Membranes were washed three times
for 10 min in PBS containing 0.5% Tween-20 between antibody steps.
Immunoreactivity was detected using the enhanced chemiluminescence
development system (Amersham). The monoclonal antibodies,
RPN1102 to vimentin and SDL3D10, speci¢c for LIII-tubulin [22]
were purchased from Amersham and Sigma, respectively. MAP2b
and tau were detected with the rabbit polyclonal antibodies, B9 [23]
and TP70 [24], respectively.
3. Results
3.1. Vimentin expression in SW13vim and SW13vim3 cells
SW13 cells are derived from a human carcinoma of the
adrenal cortex and grow in culture with the characteristic
morphology and growth pattern of epithelial cells. Vimentin
is the only detectable cytoplasmic intermediate ¢lament pro-
tein in SW13 cells and is expressed in a mosaic pattern [16,18].
Subclones of SW13 cells, either expressing vimentin or not,
have been selected by limiting dilution from the parent cell
line on the basis of the presence or absence of a vimentin
¢lament network detectable by immuno£uorescence microsco-
py [17,18]. The vimentin protein in the two clones used in this
study, SW13vim and SW13vim3, was analysed by Western
blotting of total cell lysates using a monoclonal antibody to
vimentin (Fig. 1A). Vimentin was visualised as a single band
at approximately 55 kDa in lysates from SW13vim cells (Fig.
1A, lane 1). By contrast, under similar conditions, no signal
was detected in SW13vim3 cells (Fig. 1A, lane 2). The present
study originated as part of an investigation of the e¡ects of
steroid hormones on cytoskeletal protein expression, there-
fore, in some experiments, cells were grown in steroid-depleted
medium for 48 h prior to harvesting. This was achieved by
using phenol red-free medium supplemented with DCC-
treated foetal bovine serum (DCC medium). The pattern of
vimentin expression was not a¡ected whether the cells were
grown in normal culture medium or in DCC medium (not
shown).
Presence or absence of vimentin in SW13 cells has previ-
ously been reported to be determined at the transcriptional
level [20]. This was con¢rmed by Northern blotting for the
SW13vim and SW13vim3 subclones. Total RNA from
SW13vim and SW13vim3 cells was analysed using a radio-
labeled 1.8 kb cDNA probe corresponding to the entire cod-
ing region of the human vimentin gene (Fig. 1B). A single
band of approximately 2.5 kb corresponding to vimentin
mRNA was detected in RNA from SW13vim cells (Fig.
1B, lane 1). In contrast, no hybridisation signal was visible
in the sample from SW13vim3 cells (Fig. 1B, lane 2). Taken
together, these results con¢rm that absence of vimentin in
SW13vim3 cells results from transcriptional repression and
that interconversion, which can occur between vimentin-pos-
itive and vimentin-negative cells, was minimal.
3.2. Expression of neuronal microtubular proteins in SW13
cells
An unusual, but apparently common, feature of carcinomas
of the adrenal cortex is the expression of neuronal proteins,
Fig. 1. Transcriptional control of vimentin expression in SW13vim
and SW13vim3 cells. (A) Western blot analysis of total cell lysates
from SW13vim and SW13vim3 cells using a monoclonal anti-vi-
mentin antibody con¢rming the absence of vimentin in SW13vim3
cells. (B) Northern blot analysis of total RNA from SW13vim
(lane 1) and SW13vim3 (lane 2) cells using a 1.8 kb cDNA probe
to human vimentin demonstrating transcriptional repression of vi-
mentin in SW13vim3 cells.
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such as synaptophysin, neurone-speci¢c enolase or NCAM
[25]. As SW13 cells are derived from an adrenal cortex carci-
noma and as the two subclones, SW13vim and SW13vim3,
exhibit a di¡erential pro¢le of cytoskeletal protein expression,
we sought to determine whether they expressed microtubular
proteins normally selectively expressed in neurones. We chose
to study the expression of the class III L-tubulin isoform, LIII-
tubulin, and of two microtubule-associated proteins, the high
molecular weight MAP2b and tau. Western blot analysis us-
ing an antibody speci¢c for LIII-tubulin demonstrated a single
band at approximately 55 kDa in SW13vim and SW13vim3
cells grown in normal culture medium (Fig. 2A). The amount
of LIII-tubulin present in SW13vim cells appeared to be
slightly lower than in SW13vim3 cells. By contrast, when
SW13 cells were grown in DCC medium, LIII-tubulin was still
clearly apparent in SW13vim3 cells (Fig. 2B, lane 2) but was
not readily detectable in SW13vim cells (Fig. 2B, lane 1).
A polyclonal antibody to MAP2b revealed a single band at
280 kDa on Western blots of extracts from both SW13vim
and SW13vim3 cells cultured in normal medium (Fig. 2C).
The amount of MAP2b present in each sample appeared to
be approximately equal in both cell types. When the cells were
grown in DCC medium, MAP2b was only detectable in
SW13vim3 cells and was not apparent in SW13vim cells
(Fig. 2D), and thus appears to follow the same pattern of
expression as LIII-tubulin in SW13 cells. Tau was also found
to be expressed in SW13vim and SW13vim3 cells and was
detected as a set of three bands migrating at 45^55 kDa (Fig.
2E). Unlike LIII-tubulin and MAP2b, the pattern of tau ex-
pression did not appear to be a¡ected by the type of culture
medium used (not shown). Therefore, SW13 cells express a
number of microtubular proteins normally restricted to neuro-
nal cells. Moreover, the presence of LIII-tubulin and MAP2b
in SW13 cells is correlated with the absence of vimentin ex-
pression in de¢ned culture conditions.
3.3. Analysis of LIII -tubulin transcripts
The absence of detectable LIII-tubulin protein in SW13vim
Fig. 2. Expression of neuronal microtubular proteins in SW13vim and SW13vim3 cells. (A^D) Total cell lysates and (E) heat-stable prepara-
tions from SW13vim (lane 1) and SW13vim3 (lane 2) cells. (A, C, E) Cells grown in normal medium; (B, D) cells grown in phenol red-free
medium supplemented with DCC-treated serum. Cell lysates were analysed by Western blotting using: (A, B) the LIII-tubulin-speci¢c antibody,
SDL3D10; (C, D) the B9 antibody to MAP2b; (E) the TP70 antibody to tau.
Fig. 3. Transcriptional repression of LIII-tubulin in SW13vim cells. RT-PCR analysis was performed on total RNA isolated from SW13vim
and SW13vim3 cells grown in normal medium or in phenol red-free medium supplemented with DCC-treated serum. Tubulin sequences were
ampli¢ed using pairs of primers speci¢c for K-tubulin or LIII-tubulin, yielding fragments of 253 bp and 195 bp, respectively. The sequence of
forward and reverse primers is indicated in Section 2.
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cells cultured in DCC medium may be the result of protein
degradation or of repression at the transcriptional level. To
discriminate between these two possibilities, LIII-tubulin tran-
scripts were compared by RT-PCR in SW13vim and
SW13vim3 cells. Ampli¢cation of a LIII-tubulin-speci¢c se-
quence was achieved by using a reverse primer corresponding
to the sequence encoding the isoform-determining 15 C-termi-
nal amino acids of LIII-tubulin. As a control, a cDNA frag-
ment for K-tubulin was also ampli¢ed using primers derived
from a conserved region of the protein with no homology
with L-tubulin. RT-PCR on RNA from cells grown in normal
medium produced a fragment of 195 bp corresponding to LIII-
tubulin for both SW13vim and SW13vim3 cells (Fig. 3). In
comparison, RT-PCR analysis carried out on RNA from cells
grown in DCC medium revealed a PCR ampli¢cation product
for LIII-tubulin in the sample from SW13vim3 cells only; no
similar PCR product was observed in RNA from SW13vim
cells (Fig. 3). Thus, RT-PCR results are consistent with West-
ern blot ¢ndings and show that the absence of LIII-tubulin in
vimentin-positive SW13 cells is the result of repression at the
transcriptional level.
4. Discussion
A number of microtubular proteins predominantly ex-
pressed in neurones, namely LIII-tubulin and the microtu-
bule-associated proteins, MAP2b and tau, were found to be
present in SW13 cells. Although mainly neuronal, these pro-
teins are not restricted to neurones. For instance, tau and an
isoform of MAP2 are present, albeit at low levels, in astro-
cytes [26,27]. Outside the nervous system, LIII-tubulin is ex-
pressed in testes and also in a subpopulation of chroma⁄n
cells of the adrenal medulla [28]. The latter may be explained
by the common embryonic origin of chroma⁄n cells and sen-
sory neurones. Although not arising from the same lineage as
cells from the medulla, cells from the zona glomerulosa of the
adrenal cortex display some signs of neuroendocrine di¡er-
entiation, as shown by expression of synaptophysin, neu-
rone-speci¢c enolase or NCAM [25]. Moreover, expression
of neuronal proteins appears to be a common feature of car-
cinomas of the adrenal cortex [25]. Therefore, expression of
neuronal microtubular proteins in SW13 cells, that have been
established from a carcinoma of the adrenal cortex, is consis-
tent with these observations.
Interestingly, analysis of the two SW13 cell subclones,
SW13vim and SW13vim3, revealed that LIII-tubulin expres-
sion was limited to vimentin-de¢cient cells, when the cells
were grown in phenol red-free medium supplemented with
DCC-treated foetal bovine serum. Vimentin mRNA was not
detected in SW13vim3 cells, indicating that vimentin was re-
pressed at the transcriptional level in this subclone, con¢rming
previous results obtained in a similar vimentin-negative SW13
cell subclone [20]. Likewise, RT-PCR analysis showed that the
absence of LIII-tubulin in SW13vim cells was the result of
repression at the transcriptional level. Expression of LIII-tubu-
lin at the late stages of neuronal di¡erentiation results from
the loss of a functional neurone-restrictive silencer factor
(NRSF), the zinc ¢nger trans-acting factor binding to the
NRSE in the promoter region of the LIII-tubulin gene [9,10].
On the other hand, the vimentin promoter region contains
several cis-acting silencer and anti-silencer regulatory elements
[11^15]. Anti-silencing activity overrides the e¡ect of silencers
[13,15] and contributes to vimentin induction by mitogenic
factors contained in serum that occurs in a number of cell
lines [11,14]. For example, mouse neuroblastoma NB2a cells
express vimentin in culture [29] and we have found by RT-
PCR that they expressed LIII-tubulin in DCC medium (not
shown). Thus the anti-silencing activity inducing vimentin ex-
pression does not result in LIII-tubulin repression. More likely,
vimentin and NRSF would be under the control of a similar
silencer element and SW13vim3 cells would di¡er from
SW13vim cells by the presence of a functional silencer-bind-
ing protein. This would be consistent with the pattern of vi-
mentin expression in non-metastatic versus metastatic human
breast cancer cell lines that appears to be determined by the
presence or absence of negative regulation [30]. A common
upstream silencing mechanism controlling the expression of
NRSF as well as vimentin could therefore explain the mutu-
ally exclusive expression of LIII-tubulin and vimentin in SW13
cells.
The di¡erence in expression of LIII-tubulin in SW13vim
and SW13vim3 cells was abolished in cells grown in culture
medium supplemented with normal, untreated serum. Under
these conditions, SW13vim cells as well as SW13vim3 cells
were found to express LIII-tubulin. This suggests that a factor,
present in serum and removed by DCC treatment, would ac-
tivate a transcription factor overriding the e¡ect of a silencing
element. The nature of such a factor is unknown at present,
but a steroid hormone would be a possible candidate as ste-
roids have been shown to regulate the expression of cytoskel-
etal proteins in speci¢c subpopulations of neurones. For in-
stance, estrogens up-regulate MAP2 in hypothalamic
neurones in culture [31] and testosterone up-regulates an iso-
form of L-tubulin, LII-tubulin, during axonal regeneration of
facial motor neurones after axotomy [32]. However, testoster-
one or glucocorticoids do not appear to induce LIII-tubulin
expression in SW13vim cells (data not shown). MAP2b
seems to follow the same pattern of expression as LIII-tubulin
in SW13 cells but it is unclear at present whether the absence
of the MAP2b protein in SW13vim cells is due to transcrip-
tional repression, as it is for LIII-tubulin. In contrast to
MAP2b, we did not observe any di¡erential regulation of
tau expression between vimentin-expressing and non-express-
ing SW13 cells.
The expression pattern of LIII-tubulin and vimentin in
SW13 cells appears to recapitulate the program of expression
of these two cytoskeletal proteins during neuronal develop-
ment. Vimentin is only expressed in neuronal precursors and
LIII-tubulin is characteristic of mature neurones. However,
during development, the two proteins overlap during a brief
period in newly committed neuroblasts, the stage at which
LIII-tubulin is ¢rst expressed [5,33], and when vimentin is still
present [34]. Based on the results obtained in SW13 cells, it
can be hypothesised that, in committed neuroblasts, LIII-tubu-
lin expression is controlled through the action of an extracel-
lular signal. Later in development, regulation at the transcrip-
tional level through a co-ordinated mechanism, possibly
involving silencer elements, would lead to vimentin repression
and permanent expression of LIII-tubulin in mature neurones.
Since SW13vim3 cells are devoid of cytoplasmic intermedi-
ate ¢laments, they are increasingly used to analyse the assem-
bly properties of neuronal intermediate ¢laments [35^37]. The
presence in SW13 cells of cytoskeletal proteins mainly re-
stricted to neurones should be taken into account in interpret-
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ing results obtained with this cell line as this may in£uence the
assembly of neuronal intermediate ¢laments.
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